De-escalating Breast Radiotherapy in the Age of Omission: No Retreat, Baby, No Surrender
Journal of Medical and Radiation Oncology · 10.11.2026 · 6 (1) · 23-32
DOI: 10.53011/jmro.2026.01.01 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical and Radiation Oncology, online erschienen am 31.10.2026. Verfasst von Angel Montero und 2 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
Treatment de-escalation has become a defining paradigm in contemporary breast cancer management, driven by improved outcomes, earlier diagnosis, and advances in systemic therapy, surgery, and radiotherapy. However, de-escalation is increasingly interpreted as treatment omission, with postoperative radiotherapy often becoming the first modality considered for withdrawal. This editorial argues that de-escalation should instead be viewed as a stepwise process of treatment optimization rather than a binary decision between treatment and no treatment. Modern radiotherapy already offers multiple evidence-based strategies to reduce treatment burden while preserving efficacy, and that substantially decrease treatment volume, duration, and normal tissue exposure. Omission should therefore represent the final step of de-escalation, reserved for carefully selected patients following rigorous assessment of tumor biology, validated predictive biomarkers, life expectancy, geriatric fitness, and patient preferences. The current omission debate should also be applied consistently across all treatment modalities. Emerging evidence suggests that endocrine therapy is not a toxicity-free alternative to radiotherapy and, in selected older women, may have a greater negative impact on quality of life and treatment adherence than contemporary radiotherapy. Likewise, ongoing discussions surrounding the de-escalation of surgery and even mammographic screening illustrate that the fundamental challenge extends beyond radiotherapy alone. Rather than asking when can radiotherapy be omitted? the more appropriate question is when can any component of breast cancer management be safely omitted? The future of breast cancer care lies in precision medicine that individualizes treatment while maintaining oncological efficacy, preserving quality of life, and avoiding both overtreatment and undertreatment. De-escalation should therefore represent reduction without retreat, adaptation without surrender, and precision without compromise. Key-words: Breast cancer, radiation treatment, de-escalation, optimization
Zitieren
APA
Montero, A., Ratoša, I., & Ciérvide, R. (2026). De-escalating Breast Radiotherapy in the Age of Omission: No Retreat, Baby, No Surrender. Journal of Medical and Radiation Oncology, 6(1), 23-32. https://doi.org/10.53011/jmro.2026.01.01
Vancouver
Montero A, Ratoša I, Ciérvide R. De-escalating Breast Radiotherapy in the Age of Omission: No Retreat, Baby, No Surrender. Journal of Medical and Radiation Oncology. 2026;6(1):23-32. doi:10.53011/jmro.2026.01.01
BibTeX
@article{Montero2026,
author = {Montero, Angel and Ratoša, Ivica and Ciérvide, Raquel},
title = {De-escalating Breast Radiotherapy in the Age of Omission: No Retreat, Baby, No Surrender},
journal = {Journal of Medical and Radiation Oncology},
year = {2026},
volume = {6},
number = {1},
pages = {23--32},
doi = {10.53011/jmro.2026.01.01}
}
EUVIMED